University of Oxford

ADDISON, Ill., March 24, 2025 /PRNewswire/ -- Huntleigh Healthcare is proud to announce that the world-renowned Dawes-Redman CTG Analysis™ has been approved for use in the U.S. by the Food and Drug Administration (FDA). This landmark achievement aims to assist clinicians in improving trace interpretation and preventing poor outcomes for babies and families. The Dawes-Redman CTG Analysis determines whether a non-stress test (NST) trace has met it's 'criteria of normality', derived from a database of well over 100,000 1 traces and their outcomes. The analysis evaluates factors such as basal heart rate, sinusoidal rhythms, and the short-term variation (STV) of the fetal heart rate, a factor impossible to calculate manually. "Introducing the Dawes Redman analysis to the US marks a significant milestone, leading the way for a standardized and modernized maternity care approach. This objective assessment empowers clinicians to uncover the invisible insights, offering reassurance and clarity during critical moments," commented Gang Zhang, Managing Director of Huntleigh Healthcare. The Dawes Redman™ algorithm has undergone continual refinement over the last 40 years, and is supported by over 125 peer-reviewed articles, published internationally.2 The analysis is proven to be effective at identifying fetal wellbeing, as evidenced by its high specificity.3 The University of Oxford team has further developed the analysis, allowing a healthy trace to be analyzed in as little as ten minutes, compared to the 30 minutes or more that a clinician might require. The Dawes-Redman CTG Analysis is exclusively available in Huntleigh's Sonicaid™ TEAM3 series of fetal monitors, and the OBIX BeCA® fetal monitor distributed in the USA by Clinical Computer Systems Incorporated. A Lifetime's Work Decades of development have followed the creation of the original algorithm by Professors Geoffrey Dawes and Chris Redman at Oxford University. Exclusive distribution rights for the Dawes-Redman CTG Analysis have been held by Huntleigh's Sonicaid brand since it first became commercially available and have been held by the company ever since. Gabriel Jones, Director Dawes Redman R&D University of Oxford, shared his reaction : "The entire team is delighted to see the Dawes Redman algorithm gain FDA 510(k) clearance, marking a significant step towards improving antenatal care in the U.S. For decades, our team has worked to refine this technology, ensuring it provides clinicians with a reliable, evidence-based tool for assessing fetal wellbeing. This milestone reflects the dedication of researchers and clinicians committed to advancing maternity care through innovation. We look forward to seeing the benefits of Dawes-Redman CTG analysis extend to even more patients worldwide." Globally Recognised Dawes Redman™ has been employed across the globe to improve NST interpretation and, ultimately help clinicians make life-saving decisions. It was recommended by name in the second version of NHS England's 'Saving Babies Lives' care bundle, cementing the place of computerised CTG analysis in future versions.4 Todd Blockinger, Business Unit Director for Huntleigh USA, declared: "We are tremendously excited to bring Dawes Redman to the US. We've been quite envious of our colleagues across the globe being able to offer this life-saving technology to their clinical stakeholders, so we can't wait to bring these benefits to the American maternal care communities." Read more about the Dawes Redman analysis at About Huntleigh Healthcare Ltd A proud member of the Arjo family, Huntleigh Healthcare are a UK based manufacturer and a leading global provider of innovative and high quality medical equipment for healthcare professionals. With world leading brands such as Sonicaid®, Dopplex®, Hydroven® and Smartsigns®, Huntleigh offers solutions to meet wide-ranging healthcare requirements in obstetrics, vascular assessment & treatment and patient monitoring. Huntleigh and the Sonicaid® brand have been at the forefront of maternity product innovation for over 40 years, developing a world leading range of fetal Dopplers and Monitors. Complementing this range is a suite of software systems addressing every type of maternity environment, from simple single user platforms through to fully integrated installations. 1Update from Oxford (as of Nov 24) 2Jones, Gabriel Davis, et al. "Computerized analysis of antepartum cardiotocography: a review." Maternal-Fetal Medicine 4.2 (2022): 130-140. 3 Davis Jones, G., et al. (2025), Performance evaluation of computerized antepartum fetal heart rate monitoring: Dawes–Redman algorithm at term. Ultrasound Obstet Gynecol, 65: 191-197. 4 "Saving Babies' Lives Care Bundle Version 2", Published by NHS England, March 2019. CONTACT: For more information, please contact: Todd Blockinger, Business Unit Director Tel: 224-223-2320 Email: [email protected] This information was brought to you by Cision The following files are available for download: SOURCE Arjo Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Visionary sector leaders Dan Menichella and Jo Brewer, PhD join as Non-Executive Directors Bringing strengths in strategy, immuno-oncology science execution from bench to approval, major partnerships and collaborations, and biotech scale up To support the acceleration of proof-of-concept cancer vaccine, ITOP1, into Phase I/IIa clinical development, to prevent the recurrence of oesophageal cancers OXFORD, England, March 20, 2025 /PRNewswire/ -- Infinitopes, a pioneering precision immuno-oncology company, today announced the appointments of Dan Menichella and Jo Brewer, PhD as Non-Executive Directors to its Board as the company prepares to transition into a clinical stage company with lead vaccine candidate, ITOP1, to treat patients with oesophageal cancer. Dan Menichella is a seasoned biotech executive, who brings extensive experience in vaccine development, strategic partnerships, and rapid corporate growth. As CEO and CBO of CureVac's U.S. subsidiary, he built out the Boston operation, delivered four deals in his first year – including a multi-product cancer vaccine collaboration with Eli Lilly worth up to $1.7 billion. He became CEO of CureVac AG in 2018. Before CureVac, Dan served as CBO at Bamboo Therapeutics, where he spearheaded the in-licensing of a Duchenne muscular dystrophy programme, unlocking the company's $43 million series A and subsequent $645 million buyout by Pfizer. He has significant fundraising experience and led many large transactions, including partnerships with Lilly, Biogen, and Takeda, and supported IPO's and successful exits. Dan's proven ability to forge high-value alliances and advance breakthrough therapeutics underscores his expertise in guiding life science ventures to success. Dan Menichella, incoming Non-Executive Director at Infinitopes, added: "I am honoured to join Infinitopes' Board of Directors at this exciting time for the company, as we begin the Phase I/IIa clinical trial in oesophageal cancer. Infinitopes is a highly innovative company with a strong commitment to cancer research. Its approach holds the promise to revolutionise cancer treatments for patients, and I am excited and committed to support Jonathan and the team as they embark on this groundbreaking path." Jo Brewer, PhD, is a recognised industry leader in cancer immunotherapy and cell therapies, with over 20 years of experience bringing cutting-edge treatments from discovery to the clinic. Currently serving as CSO at Adaptimmune, she has been instrumental in developing autologous and allogeneic T-cell therapies, leading to Tecelra®, the first engineered TCR-T cell therapy for solid tumours to reach the market. As a founding scientist at Adaptimmune, Jo played a critical role in the development of multiple immunotherapies, including lete-cel for sarcoma and uza-cel, now partnered with Galapagos. She has built and led multiple research teams at Adaptimmune and played a significant role in the upscaling from a small biotech to 500+ employees, driving innovation across discovery and translational science. Jo Brewer, PhD, incoming Non-Executive Director at Infinitopes, remarked: "Infinitopes, with its pioneering approach to precision cancer vaccines, driven by its innovative AI/ML-powered Immunomics™ platform, has the potential to revolutionise how we target and treat cancers. The precision and speed that its world-leading clinicians and scientists are advancing its novel immunotherapies is truly impressive, and I look forward to joining the Board at such a critical time of clinical development, to contribute my expertise to bringing these transformative treatments to patients." Jonathan Kwok, Chief Executive Officer & Co-Founder at Infinitopes, said : "I'm delighted to welcome Dan and Jo to our Board at a pivotal time, as we prepare to begin our first clinical trial for ITOP1, our proof-of-concept cancer vaccine candidate, initially targeting oesophageal cancers. Their leadership and deep expertise in immuno-oncology and biotech growth is invaluable as we advance our AI/ML-driven antigen discovery platform and push the boundaries of what is possible in cancer vaccine development. Their decision to join Infinitopes reflects the strength of our technologies, our ambitious mission, and the future potential impact for patients worldwide." In April 2024 Infinitopes announced its oversubscribed £12.8 million seed financing to advance its AI/ML Precision Immunomics™ bespoke antigen discovery platform. This proprietary technology enables the safe and highly accurate design of 'best-in-class' therapeutics for multiple cancer indications. Guided by an exceptional leadership team and distinguished Scientific Advisory Board (SAB) of world-class clinicians, scientists, and regulatory experts, Infinitopes is poised to initiate its vaccine candidate, ITOP1, in a highly anticipated double-blind, randomised, placebo-controlled Phase I/IIa clinical trial. This trial is aimed at treating patients with oesophageal cancer and is expected to begin at four UK NHS university cancer centres in the first half of 2025. About Infinitopes Infinitopes Ltd is a soon to be clinical stage, integrated cancer biotechnology company supported by Cancer Research UK (CRUK) and the University of Oxford. The Company combines two world leading platforms, in precision target discovery and in high efficiency, vector delivery systems, to develop immunologically durable vaccines against multiple solid tumour indications. The lead vaccine candidate is expected to begin Phase I/IIa trials in H1' 25. Infinitopes has gathered together in-house talent across antigen discovery, immunology, vaccinology, oncology, biomanufacturing, clinical trials and regulation, winning an 'Innovative Licensing and Access Pathway' (ILAP) innovation passport from the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in 2022. Infinitopes has also won two prestigious, maximum size, nondilutive awards from Innovate UK, a Cancer Therapeutics Award (in 2022) and a Future Economy Investor Partnership (in 2023). Since incorporation, the Infinitopes team has raised nearly $20m from sector expert investors including Cancer Research Horizons, Cancer Research Institute, Kindred Capital, Manta Ray Ventures, Martlet, Meltwind, Octopus Ventures, Saras Capital, Wilbe and the Fundación CRIS Contra el Cáncer, funding its rapid growth from three academic co-founders to 28 full time equivalents. It is now the largest tenant of Oxford University's BioEscalator innovation accelerator. For more information, visit SOURCE Infinitopes WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Collaboration enhances efficiency and quality in liver recovery and availabilityOXFORD, United Kingdom and NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- OrganOx Ltd., the pioneering company transforming organ transplantation and care with innovative technology, has announced a new partnership with ProCure On-Demand, a leading comprehensive organ recovery service provider in the U.S. The collaboration aims to significantly improve the recovery and assessment of livers for transplantation by combining OrganOx’s cutting-edge normothermic machine perfusion (NMP) technology with ProCure’s advanced surgical, perfusion, preservation, and logistics solutions. Through this partnership, OrganOx will support ProCure’s nationwide clinical teams by providing education and certification through its exclusive training program. This collaboration will offer transplant centers and Organ Procurement Organizations (OPOs) additional clinical services to aid in the recovery process, ultimately aiming to improve transplant outcomes for more patients. “Increasing the number of healthy, viable livers available for transplant is crucial as the global incidence of liver disease continues to rise,” said Craig Marshall, Chief Executive Officer of OrganOx. “Our partnership with ProCure On-Demand brings together a flexible range of high-quality services and resources to meet the unique needs of clinical teams and organizations, ensuring more successful transplants.” “We are excited to be partnering with an innovator like OrganOx,” commented Dr. Zachary Kon, ProCure’s CEO and Co-Founder. “We share many of the same foundational values including a commitment to saving lives by ensuring that every organ counts. Together, we are focused on making the liver transplant waitlist a thing of the past.” About OrganOxOrganOx is a commercial stage organ technology company, spun out of the University of Oxford in 2008, dedicated to developing technologies to improve outcomes for patients with acute or chronic organ failure. The OrganOx metra® is a normothermic machine perfusion (NMP) platform approved in the U.S., Europe, Canada, and Australia. It has been utilized in over 5,000 liver transplants to date to keep donor livers in a metabolically active state outside the body so that functional assessment of the organ can be performed prior to transplant, enabling an increased number of organs available for transplant. Learn more at www.organox.com. About ProCure On-DemandProCure On-Demand is transforming the organ transplant ecosystem and enabling more thoracic and abdominal organs to reach recipients in need. Founded as a Public Benefit Corporation, ProCure provides professional, high-quality organ recovery services worthy of the first step in the transplant process. ProCure’s flexible model offers a nationwide network of recovery surgeons and clinical professionals, advanced logistics and engagement with innovative technology solutions enabling more patients to receive the transplants they need. For more information, visit www.procureodx.com. ContactsOrganOx Investor Relations: Steve Deitsch Chief Financial Officer, OrganOx investorrelations@organox.com OrganOx Media:Emma YangHealth+Commerceemma@healthandcommerce.comProCure Media:Aaron CohenAaron Cohen PRaaroncohenPR@gmail.com301-633-6773